0KBS Stock Chart & Stats
€50.40
€0.25(0.48%)
At close: 4:00 PM EST
€50.40
€0.25(0.48%)
Day’s Range― - ―
52-Week Range€43.78 - €55.10
Previous CloseN/A
Volume7.51K
Average Volume (3M)7.60K
Market Cap
€10.87B
Enterprise Value€12.60K
Total Cash (Recent Filing)€391.38M
Total Debt (Recent Filing)€2.31B
Price to Earnings (P/E)21.7
Beta0.75
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.43
Shares Outstanding209,125,150
10 Day Avg. Volume8,262
30 Day Avg. Volume7,601
Financial Highlights & Ratios
PEG Ratio3.24
Price to Book (P/B)5.20
Price to Sales (P/S)3.81
P/FCF Ratio19.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€50.00Price Target Upside-0.79% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)3.17
Revenue Forecast (FY)€2.78B
Bulls Say, Bears Say
Bulls Say
Sustained ProfitabilityRecordati’s consistently high gross, EBITDA and net margins indicate a strong branded and rare-disease portfolio. This profitability supports reinvestment, resilience against cost pressure and continued cash generation over the medium term.
Strong Cash GenerationPositive free cash flow across periods, including strong TTM generation, shows that reported earnings are generally backed by cash. This provides funding for product development, debt service and portfolio expansion without relying solely on external capital.
Growth And Shareholder ReturnsRevenue and earnings growth, combined with high recent return on equity, suggests effective use of the company’s commercial platform and specialty portfolio. Sustained growth can strengthen operating scale and support shareholder returns over the next several quarters.
Bears Say
Meaningful LeverageAlthough leverage has improved from 2024–2025, debt remains materially higher than in 2023. This increases financial risk, can constrain acquisition or investment flexibility and makes the company more exposed to refinancing and interest-cost pressure.
Cash Flow VariabilityThe history of uneven free cash flow and relatively low TTM operating cash flow coverage indicates that cash conversion is not uniformly dependable. This may reduce the cushion available for debt reduction, dividends and investment during weaker periods.
Margins Below PeakMargins remain strong but have not returned to the 2021 peak, pointing to possible product-mix or cost pressure. If this persists, it could limit earnings conversion from revenue growth and weaken the benefits of the company’s otherwise attractive portfolio.
Recordati Industria Chimica e Farmaceutica SPA News
0KBS FAQ
What was Recordati Industria Chimica e Farmaceutica SPA’s price range in the past 12 months?
Recordati Industria Chimica e Farmaceutica SPA lowest share price was €43.78 and its highest was €55.10 in the past 12 months.
What is Recordati Industria Chimica e Farmaceutica SPA’s market cap?
Recordati Industria Chimica e Farmaceutica SPA’s market cap is €10.87B.
When is Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date?
Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date is Nov 10, 2026 which is in 73 days.
How were Recordati Industria Chimica e Farmaceutica SPA’s earnings last quarter?
Recordati Industria Chimica e Farmaceutica SPA released its earnings results on Jul 28, 2026. The company reported €1.292 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Recordati Industria Chimica e Farmaceutica SPA overvalued?
According to Wall Street analysts Recordati Industria Chimica e Farmaceutica SPA’s price is currently Overvalued.
Does Recordati Industria Chimica e Farmaceutica SPA pay dividends?
Recordati Industria Chimica e Farmaceutica SPA does not currently pay dividends.
What is Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate?
Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recordati Industria Chimica e Farmaceutica SPA have?
Recordati Industria Chimica e Farmaceutica SPA has 209,125,150 shares outstanding.
What happened to Recordati Industria Chimica e Farmaceutica SPA’s price movement after its last earnings report?
Recordati Industria Chimica e Farmaceutica SPA reported an EPS of €1.292 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.292%.
Which hedge fund is a major shareholder of Recordati Industria Chimica e Farmaceutica SPA?
Currently, no hedge funds are holding shares in GB:0KBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
0KBS Stock 12 Month Forecast
Average Price Target
€50.00
▼(-0.79% Downside)